Depression Side Effect Labeling Awareness Act of 2018

Fact Sheet API

Bill Number

HR 6717

Introduced

Sep 6, 2018

Latest Action

Referred to the House Committee on Energy and Commerce.

Sponsor

Cosponsors

Topics

Administrative law and regulatory procedures Consumer affairs Department of Health and Human Services Drug safety, medical device, and laboratory regulation Food and Drug Administration (FDA) Health Mental health

Full Text

View Full Bill Text

Votes

Summary

Depression Side Effect Labeling Awareness Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act to require the label of a drug that has an increased risk of suicide or depression to prominently display such risk.

Actions

Sep 6, 2018

Referred to the House Committee on Energy and Commerce.
Sep 6, 2018

Introduced in House

Amendments

Related Bills